Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Bristol-myers squibb company symbols : Ayla save search
Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
Published: 2023-11-06 (Crawled : 13:00) - globenewswire.com
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.61%
H: 0.77%
C: -0.66%
ADXS | $0.54 12.48% 950
|
Health Technology
|
| O: 6.74%
H: 0.0%
C: -10.53%
al102 drug tumors pharmaceuticals designation
Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023
Published: 2023-10-23 (Crawled : 11:00) - globenewswire.com
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.19%
H: 0.66%
C: -0.62%
ADXS | $0.54 12.48% 950
|
Health Technology
|
| O: 0.0%
H: 5.56%
C: 0.0%
al102 congress tumors pharmaceuticals trial results phase 2
Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023
Published: 2023-08-01 (Crawled : 12:00) - globenewswire.com
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 1.81%
H: 0.0%
C: 0.0%
al102 presentation pharmaceuticals al101
Ayala Pharmaceuticals and Biosight Enter into Definitive Merger Agreement
Published: 2023-07-27 (Crawled : 12:20) - globenewswire.com
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -3.21%
H: 2.51%
C: -0.44%
ADXS | $0.54 12.48% 950
|
Health Technology
|
| O: 6.93%
H: 3.7%
C: 1.85%
pharmaceuticals agreement
Ayala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid Tumors
Published: 2023-07-05 (Crawled : 12:00) - globenewswire.com
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.19%
H: 1.07%
C: 0.65%
ADXS | $0.54 12.48% 950
|
Health Technology
|
| O: 1.24%
H: 0.0%
C: -7.09%
al102 fda tumors treatment pharmaceuticals meeting phase 2
Updated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2023-06-05 (Crawled : 12:00) - globenewswire.com
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.37%
H: 0.85%
C: 0.12%
ADXS | $0.54 12.48% 950
|
Health Technology
|
| O: -2.73%
H: 4.42%
C: -0.4%
meeting results phase 2
Ayala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2023-05-25 (Crawled : 21:00) - globenewswire.com
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.08%
H: 0.71%
C: -1.07%
ADXS | $0.54 12.48% 950
|
Health Technology
|
| O: 1.01%
H: 17.5%
C: -15.0%
pharmaceuticals meeting results phase 2
Ayala Pharmaceuticals Announces RINGSIDE Results to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2023-04-27 (Crawled : 13:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -0.6%
ADXS | $0.54 12.48% 950
|
Health Technology
|
| O: 3.39%
H: 0.0%
C: -7.38%
pharmaceuticals meeting results
Ayala Pharmaceuticals Announces Data on AL101 in Adenoid Cystic Carcinoma (ACC) at 2022 ASCO Annual Meeting
Published: 2022-06-06 (Crawled : 16:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 1.03%
H: 0.0%
C: 0.0%
AYLA | $0.5036 5.84% -0.7% 0
|
Health Technology
|
| O: 0.0%
H: 3.42%
C: 2.33%
al101 asco
Ayala Pharmaceuticals Announces Poster Presentation on AL101 at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2022-04-27 (Crawled : 15:00) - globenewswire.com
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.28%
H: 0.65%
C: 0.01%
AYLA | $0.5036 5.84% -0.7% 0
|
Health Technology
|
| O: -3.11%
H: 4.36%
C: -1.79%
al101 presentation
Ayala Pharmaceuticals Presents Preliminary Clinical Data from the Ongoing Phase 2 ACCURACY Trial and Announces Pre-Clinical Proof of Concept Data for Enhanced Activity of AL101 in Combination with Approved Cancer Therapies in ACC
Published: 2021-09-16 (Crawled : 14:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.23%
H: 0.31%
C: -1.02%
AYLA | $0.5036 5.84% -0.7% 0
|
Health Technology
|
| O: 0.71%
H: 5.25%
C: -14.35%
phase 2 ongoing pre-clinical cancer proof of concept trial preclinical
Ayala Pharmaceuticals to Present Clinical Data from Ongoing Phase 2 ACCURACY Trial and New Preclinical Results from Combination Study of AL101 at the European Society for Medical Oncology (ESMO) Virtual Congress 2021
Published: 2021-09-01 (Crawled : 12:15) - globenewswire.com
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.64%
H: 0.0%
C: -2.2%
AYLA | $0.5036 5.84% -0.7% 0
|
Health Technology
|
| O: -2.6%
H: 6.97%
C: 6.81%
phase 2 europe ongoing results trial preclinical pre-clinical
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.